BioCatalyst

Navtemadlin, Navtemadlin placebo, Ruxolitinib — catalyst calendar

1 verified catalyst event(s) referencing Navtemadlin, Navtemadlin placebo, Ruxolitinib, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-31
in 3mo
ESTIMATED
 READOUT
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With
Phase 3 · Myelofibrosis, Post-PV MF
 Kartos Therapeutics, Inc. Navtemadlin, Navtemadlin placebo, Ruxoli ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.